1.Clinical epidemiology of gastric cancer.
Tiing Leong ANG ; Kwong Ming FOCK
Singapore medical journal 2014;55(12):621-628
Gastric cancer is the second leading cause of cancer-related mortality and the fourth most common cancer globally. There are, however, distinct differences in incidence rates in different geographic regions. While the incidence rate of gastric cancer has been falling, that of gastric cardia cancers is reportedly on the rise in some regions. Helicobacter pylori (H. pylori) infection is a major risk factor of non-cardia gastric cancer, and data has emerged concerning the role of H. pylori eradication for primary prevention of gastric cancer. Dietary, lifestyle and metabolic factors have also been implicated. Although addressing these other factors may contribute to health, the actual impact in terms of cancer prevention is unclear. Once irreversible histological changes have occurred, endoscopic surveillance would be necessary. A molecular classification system offers hope for molecularly tailored, personalised therapies for gastric cancer, which may improve the prognosis for patients.
Female
;
Global Health
;
Helicobacter Infections
;
complications
;
prevention & control
;
Helicobacter pylori
;
Humans
;
Incidence
;
Male
;
Obesity
;
complications
;
Risk Factors
;
Stomach Neoplasms
;
epidemiology
;
genetics
;
microbiology
;
prevention & control
2.Roadmap for elimination of gastric cancer in Korea.
The Korean Journal of Internal Medicine 2015;30(2):133-139
Most gastric cancers are caused by infection with the common human bacterial pathogen, Helicobacter pylori. It is now accepted that gastric cancer can be prevented and virtually eliminated by H. pylori eradication and this knowledge was responsible for country-wide H. pylori eradication combined with secondary cancer prevention for those with residual risk that was introduced in Japan in 2013. Korea is a high H. pylori prevalence and high gastric cancer incidence country and a good candidate for a gastric cancer elimination program. The presence of an H. pylori infection is now considered as an indication for treatment of the infection. However, antimicrobial drug resistance is common among H. pylori in Korea making effective therapy problematic. Country-wide studies of the local and regional antimicrobial resistance patterns are needed to choose the most appropriate therapies. H. pylori and gastric cancer eradication can be both efficient and cost effective making it possible and practical to make Korea H. pylori and gastric cancer free. There is no reason to delay.
Anti-Bacterial Agents/*therapeutic use
;
Disease Eradication
;
Drug Resistance, Bacterial
;
Helicobacter Infections/*drug therapy/epidemiology/microbiology
;
Helicobacter pylori/*drug effects/growth & development
;
Humans
;
Prevalence
;
Primary Prevention/*methods
;
Republic of Korea/epidemiology
;
Risk Assessment
;
Risk Factors
;
Stomach Neoplasms/epidemiology/microbiology/*prevention & control
;
Treatment Outcome